Advocating for mutually beneficial access to shelved compounds

Future Med Chem. 2018 Jun 1;10(12):1395-1398. doi: 10.4155/fmc-2018-0090. Epub 2018 May 23.
No abstract available

Keywords: drug industry; drug repurposing; government regulation; nelivaptan; shelved compounds; tax incentives.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antidiuretic Hormone Receptor Antagonists / therapeutic use
  • Anxiety Disorders / drug therapy
  • Depressive Disorder, Major / drug therapy
  • Drug Industry
  • Drug Repositioning* / methods
  • Humans
  • Indoles / therapeutic use
  • Pyrrolidines / therapeutic use
  • Receptors, Vasopressin / therapeutic use

Substances

  • 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide
  • AVPR1b protein, human
  • Antidiuretic Hormone Receptor Antagonists
  • Indoles
  • Pyrrolidines
  • Receptors, Vasopressin